Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

August 22, 2013 updated by: Forest Laboratories

A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
568

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 1Z9
        • Forest Investigative Site 025
    • Nova Scotia
      • Sydney, Nova Scotia, Canada, B1S 2EB
        • Forest Investigative Site 036
    • Ontario
      • Chatham, Ontario, Canada, N7M 1B7
        • Forest Investigative Site 006
      • Ottawa, Ontario, Canada, K1G 4G3
        • Forest Investigative Site 003
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35216
        • Forest Investigative Site 039
    • California
      • Beverly Hills, California, United States, 90210
        • Forest Investigative Site 037
      • Encino, California, United States, 91316
        • Forest Investigative Site 012
      • Newport Beach, California, United States, 92660
        • Forest Investigative Site 038
      • Oceanside, California, United States, 92056
        • Forest Investigative Site 024
      • Redlands, California, United States, 92374
        • Forest Investigative Site 001
      • San Diego, California, United States, 92108
        • Forest Investigative Site 031
      • Sherman Oaks, California, United States, 91403
        • Forest Investigative Site 050
    • Connecticut
      • Cromwell, Connecticut, United States, 06416
        • Forest Investigative Site 034
    • Florida
      • Coral Springs, Florida, United States, 33067
        • Forest Investigative Site 021
      • Fort Myers, Florida, United States, 33912
        • Forest Investigative Site 043
      • Gainesville, Florida, United States, 32607
        • Forest Investigative Site 018
      • Hallandale Beach, Florida, United States, 33009
        • Forest Investigative Site 060
      • Jacksonville, Florida, United States, 32216
        • Forest Investigative Site 020
      • Ocala, Florida, United States, 34471
        • Forest Investigative Site 005
      • Orlando, Florida, United States, 32806
        • Forest Investigative Site 014
      • Orlando, Florida, United States, 32806
        • Forest Investigative Site 028
    • Georgia
      • Atlanta, Georgia, United States, 30328
        • Forest Investigative Site 046
    • Illinois
      • Chicago, Illinois, United States, 60634
        • Forest Investigative Site 041
      • Chicago, Illinois, United States, 60640
        • Forest Investigative Site 054
      • Hoffman Estates, Illinois, United States, 60169
        • Forest Investigative Site 026
    • Indiana
      • Indianapolis, Indiana, United States, 46260
        • Forest Investigative Site 045
    • Kansas
      • Prairie Village, Kansas, United States, 66206
        • Forest Investigative Site 056
    • Massachusetts
      • Haverhill, Massachusetts, United States, 01830
        • Forest Investigative Site 049
    • New Jersey
      • Cherry Hill, New Jersey, United States, 08002
        • Forest Investigative Site 044
      • Willingboro, New Jersey, United States, 08046
        • Forest Investigative Site 023
    • New York
      • Brooklyn, New York, United States, 11214
        • Forest Investigative Site 004
      • Mount Kisco, New York, United States, 10549
        • Forest Investigative Site 002
      • New York, New York, United States, 10021
        • Forest Investigative Site 051
      • New York City, New York, United States, 10003
        • Forest Investigative Site 016
      • Orangeburg, New York, United States, 10962
        • Forest Investigative Site 042
    • North Carolina
      • Raleigh, North Carolina, United States, 27607
        • Forest Investigative Site 061
    • Ohio
      • Dayton, Ohio, United States, 45417
        • Forest Investigative Site 010
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73112
        • Forest Investigative Site 048
    • Oregon
      • Portland, Oregon, United States, 97210
        • Forest Investigative Site 053
      • Salem, Oregon, United States, 97301
        • Forest Investigative Site 017
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18104
        • Forest Investigative Site 011
      • Bridgeville, Pennsylvania, United States, 15017
        • Forest Investigative Site 052
      • Philadelphia, Pennsylvania, United States, 19107
        • Forest Investigative Site 027
    • Rhode Island
      • Lincoln, Rhode Island, United States, 02865
        • Forest Investigative Site 059
    • Tennessee
      • Memphis, Tennessee, United States, 38119
        • Forest Investigative Site 029
    • Texas
      • Dallas, Texas, United States, 75231
        • Forest Investigative Site 009
      • San Antonio, Texas, United States, 78229
        • Forest Investigative Site 007
      • San Antonio, Texas, United States, 78229
        • Forest Investigative Site 035
    • Washington
      • Bellevue, Washington, United States, 98007
        • Forest Investigative Site 022
      • Seattle, Washington, United States, 98104
        • Forest Investigative Site 055
      • Spokane, Washington, United States, 99204
        • Forest Investigative Site 057

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women, 18-75 years old
  • Currently meet the DSM-IV-TR criteria for Major Depressive Disorder
  • The patient's current depressive episode must be at least 6 weeks in duration

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control.
  • Patients who are considered a suicide risk
  • Patients with a history of meeting DSM-IV-TR criteria for
  • a. any manic or hypomanic episode
  • b. schizophrenia or any other psychotic disorder
  • c. obsessive-compulsive disorder.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: 3
Placebo
Drug: Placebo
Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Experimental: 1
40mg Levomilnacipran ER
Drug: Levomilnacipran ER
Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Drug: Levomilnacipran ER
Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Experimental: 2
80mg of Levomilnacipran ER
Drug: Levomilnacipran ER
Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Drug: Levomilnacipran ER
Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.
Time Frame: From Baseline to Week 8
The Montgomery-Asberg Depression Rating Scale (MADRS) rates patients on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item was scored on a 7-point scale. A score of 0 indicated the absence of symptoms, and a score of 6 indicated symptoms of maximum severity. The minimum overall score possible was 0 (absence of symptoms), with a maximum overall score of 60 (maximum severity).
From Baseline to Week 8

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Sheehan Disability Scale (SDS) Total Score
Time Frame: From Baseline to Week 8
The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)
From Baseline to Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Forest Laboratories

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Carl Gommoll, MS, Forest Research Institute, a subsidiary of Forest Laboratories

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2011

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2012

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2012

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 10, 2011

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 17, 2011

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 21, 2011

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 29, 2013

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 22, 2013

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • LVM-MD-10

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings